ClinicalTrials.gg
RecruitingNCT07553442Updated Nov 12, 2026

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

A Phase 2 interventional study of ALN-AGT01 RVR and Placebo in Hypertension, sponsored by Alnylam Pharmaceuticals. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Planned enrollment
909th of 1,779
93 · median 100
Started
2026
with 100 others
Phase 2
170 of 2,031
21 open now
Primary completion
2028-04
later than 251 of 367 live
Registered
1,979th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 909th largest by planned enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2026, is one of 170 in phase 2, reaches primary completion later than 251 of the 367 other live ones, and was the 1,979th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Read the detailed description

This study will be conducted in 2 parts:

  • Part A: Single dose (SD), dose-ranging part in adults with mild to moderate hypertension.
  • Part B: SD in adults with mild to moderate hypertension.
03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • RNAi therapeutic
  • oligonucleotide
  • Reversir
  • Zilebesiran
  • ALN-AGT01
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part A: Inclusion Criteria

  • Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
  • Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications

Part B: Inclusion Criteria

  • Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
  • Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks

Both Parts: Exclusion Criteria

  • Has known secondary hypertension or serum potassium more than 5 mmol/L
  • Has an estimated (eGFR) less than 30 mL/min/1.73m\^2

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    ALN-AGT1 RVR

    Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR.

    Drug: ALN-AGT01 RVR · Drug: Zilebesiran

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of zilebesiran followed by a single dose of placebo.

    Drug: Placebo · Drug: Zilebesiran

Interventions

  • DrugALN-AGT01 RVR

    ALN-AGT01 RVR will be administered subcutaneously (SC)

  • DrugPlacebo

    Placebo will be administered SC

  • Zilebesiran will be administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Percentage recovery from baseline in serum AGT

    Time frame: Up to Day 4

  2. Part B: Percentage recovery from baseline in mean seated office SBP

    Time frame: At Day 4 and Day 7

Secondary outcomes

  1. Both Parts: Frequency of Adverse Events (AEs)

    Time frame: Up to 10 months

  2. Part A: Percentage recovery from baseline in serum AGT

    Time frame: Up to Day 7

  3. Part B: Percentage recovery from baseline in serum AGT

    Time frame: At Day 4 and Day 7

  4. Part B: Change from baseline in mean seated office SBP

    Time frame: At Day 4 and Day 7

07

Study locations

1 of 3 sites recruiting
  • Clinical Trial Site
    Lake Forest, California 92630, United States
    Recruiting
  • Clinical Trial Site
    Tampa, Florida 33613, United States
    Active, not recruiting

    Not enrolling at this site.

  • Clinical Trial Site
    Savannah, Georgia 31405, United States
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 23 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 28, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553442
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Apr 27, 2026
Primary completion
Apr 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion